Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

reated patients. The primary endpoint was ORR and secondary endpoints included CBR, TTP, DOR, OS and safety.
  • The 003-A1 study was an open-label, single-arm Phase 2b trial. The trial evaluated 266 heavily-pretreated patients with relapsed and refractory multiple myeloma who had received at least two prior therapies, including bortezomib and either thalidomide or lenalidomide. Refractory disease was defined as less than or equal to a 25 percent response or progression during therapy, or progression within 60 days after completion of therapy.[ii]  The primary endpoint was ORR. Secondary endpoints included DOR, CBR, OS, TTP, PFS, and safety. 
  • The 007 study is an open-label Phase 1b/2 study. Results were reported from the dose-expansion phase of this ongoing study, which evaluated the safety and efficacy of a prolonged, 30-minute infusion of carfilzomib at a dose of 56mg/m(2). Endpoints included ORR, DOR, PFS, TTP, pharmacokinetics and safety.
  •  

    ASH Investor Teleconference
    Investigators and members of the Onyx management team will highlight data presented on carfilzomib featured at the 53rd ASH Annual Meeting and Exposition in San Diego, CA. The teleconference will begin at 10:00 a.m. PT on December 13, 2011.

    Interested parties may access the teleconference and the presentation that accompanies it on our website at:  

    http://www.onyx-pharm.com/investors/event-calendar

    or by dialing 847-585-4405 and using the passcode 31296220.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 31296220# later in the day.  The replay will be available on the Onyx website until December 27, 2011.

    Carfilzomib Development Program
    Carfilzomib is being studied in several clinical trials either as a single-agent or in combi
    '/>"/>

    SOURCE Onyx Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/5/2015)... YORK , March 5, 2015  As ... set of regulations, Ethics & Compliance professionals are ... to a new survey issued today by LRN, ... and education. An overwhelming majority of respondents expressed ... the most important component of E&C training programs ...
    (Date:3/5/2015)...   ndd Medical Technologies , a leader in ... ultrasound technology, announced that its EasyOne Pro® was used ... Antonio Pulmonary Fibrosis Support Group. The clinic targeted patients ... as well as those suspected of having ILD or ... 12 square inches, EasyOne Pro provides accurate respiratory test ...
    (Date:3/5/2015)... , March 5, 2015  Celsion Corporation ... the Company will host a conference call to ... update on its development programs for ThermoDox®, its ... newly acquired technology platforms, TheraPlas™ and TheraSilence™, in ... on Thursday, March 12, 2015. To participate in ...
    Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 2ndd Medical Technologies' Mobile Pulmonary Function Testing Helps Combat Pulmonary Fibrosis 3Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2
    ... dba Discharge 1-2-3 of Schaumburg, IL, has ... 2011 Chicago Innovation Awards.  The ten winners will be announced ... Harris Theater that evening. The Chicago Innovation Awards, ... of the most innovative new products or services brought to ...
    ... FDA Commissioner Margaret A. Hamburg, M.D., today ... be taken to drive biomedical innovation, while improving ... Titled "Driving Biomedical Innovation: Initiatives for ... about the sustainability of the medical product development ...
    Cached Medicine Technology:Callibra, Inc. dba Discharge 1-2-3™ is Named Top 75 Nominee for 10th Annual Chicago Innovation Awards 2FDA Commissioner Outlines Steps to Spur Biomedical Innovation, Improve Health of Americans 2
    (Date:3/5/2015)... MS (PRWEB) March 05, 2015 At ... Basics and Beyond,” leaders in addiction treatment met today ... updates in best clinical practices. Among the numerous respected ... , who will address the role that pain medications ... and new evidence-based treatment options. , "It is hard ...
    (Date:3/5/2015)... March 05, 2015 Califia Farms ... in the natural products coffee drinks category[1], today unveils ... Expo West in Anaheim, Calif. Concentrated Cold Brew ... Califia Café, which democratizes the next wave of the ... they need to become their own baristas. , ...
    (Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
    (Date:3/5/2015)... 05, 2015 INTEGRATED Healthcare Strategies, ... to participate in its 2015 Children’s Hospitals Executive ... and director-level positions, and the survey results are ... report featured data on 60 executive and director ... organizations and 7 subsidiary children’s hospitals. Additionally, it ...
    (Date:3/5/2015)... San Diego, CA (PRWEB) March 05, 2015 ... that it is now running on 100% pollution-free ... provider, Arcadia Power. , As an Arcadia ... Environmental Protection Agency’s (EPA) Green Power Partnership requirements, ... and Starbucks that also purchase clean energy. Earth ...
    Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 2Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 3Health News:Califia Farms Personalizes At-Home Coffee Experience with the Launch of Concentrated Cold Brew Coffee 4Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Participation Is Now Open For INTEGRATED Healthcare Strategies 2015 Children’s Hospitals Executive Compensation Survey 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2
    ... to read will be one of the topics of a ... is co-sponsored by the UC Davis Center for Mind and ... and Visual Learning, and the departments of psychology and linguistics ... learning to read, said David Corina, professor in the Department ...
    ... , TUESDAY, Nov. 15 (HealthDay News) -- High doses of ... of plaque in coronary arteries and reversed the progression of ... 1,385 patients who took either 40 milligrams (mg) of Crestor ... followed for two years. The major finding was that ...
    ... a significant decrease in the function of the serotonin system ... that regulates such functions as impulse control and mood. It ... men. This is the conclusion of multidisciplinary research carried out ... the University of Gothenburg, Sweden. The research group in ...
    ... Nov. 15 (HealthDay News) -- ,Elite female marathon runners have ... women, a new study finds. This type of plaque ... common type of heart disease and the leading cause of ... Heart Institute study found that elite male marathoner runners may ...
    ... specific community-based screening may increase awareness of the dangers of ... in the November 2011 issue of Otolaryngology-Head and Neck ... 60 to 80% of head and neck cancers could be ... national programs to date have had little impact reducing these ...
    ... into any cell type in the body, rely heavily ... activities. In contrast, mature cells in children ... sugar and oxygen into carbon dioxide and water during ... metabolic needs. How cells progress from one ...
    Cached Medicine News:Health News:Visual language, cognition and deaf education topics of summit 2Health News:High Doses of Statins Tied to Less Arterial Plaque in Study 2Health News:Women Marathon Runners Have Less Artery Plaque: Study 2Health News:Population-specific community-based cancer screening may discourage smoking 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 2Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 3Health News:UCLA stem cell researchers uncover mechanism that regulates human pluripotent stem cell metabolism 4
    ... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
    ... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    Medicine Products: